Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen-receptor Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01124695
What this trial is testing

Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

Who this might be right for
Breast CancerStage IV Breast Cancer
ECOG-ACRIN Cancer Research Group 124
Large-scale testing (Phase 3)UnknownNCT02132000
What this trial is testing

Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients

Who this might be right for
Breast Cancer Patients in PremenopausalEstrogen and/or Progesterone Receptor Positive
Fengxi Su 3,036
Testing effectiveness (Phase 2)Ended earlyNCT02774681
What this trial is testing

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

Who this might be right for
Breast Carcinoma Metastatic in the BrainEstrogen Receptor NegativeHER2/Neu Negative+4 more
Northwestern University 12
Testing effectiveness (Phase 2)Ended earlyNCT04191382
What this trial is testing

Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer

Who this might be right for
Breast Cancer
Sanofi 105
Large-scale testing (Phase 3)Study completedNCT00553358
What this trial is testing

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 455
Testing effectiveness (Phase 2)Study completedNCT00371345
What this trial is testing

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Who this might be right for
Breast CancerMetastasis
Bristol-Myers Squibb 92
Testing effectiveness (Phase 2)Study completedNCT02648477
What this trial is testing

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more
City of Hope Medical Center 30
Not applicableWithdrawnNCT00899639
What this trial is testing

Studying Tumor Tissue Samples From Patients With Early-Stage Breast Cancer

Who this might be right for
Breast Cancer
Rutgers, The State University of New Jersey
Testing effectiveness (Phase 2)Ended earlyNCT02345772
What this trial is testing

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy

Who this might be right for
HER2-positive Breast CancerER-positive Breast Cancer
Western Regional Medical Center 4
Testing effectiveness (Phase 2)Study completedNCT02718144
What this trial is testing

Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer

Who this might be right for
Breast Neoplasms
Pantarhei Oncology B.V. 12
Very early researchStudy completedNCT02538484
What this trial is testing

Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects

Who this might be right for
Breast Cancer
The University of Texas Health Science Center at San Antonio 24
Testing effectiveness (Phase 2)UnknownNCT04997798
What this trial is testing

Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer

Who this might be right for
Breast CancerEstrogen Receptor Positive TumorHER2-positive Breast Cancer
First Affiliated Hospital of Zhejiang University 30
Testing effectiveness (Phase 2)Ended earlyNCT01662726
What this trial is testing

Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth

Who this might be right for
Breast Neoplasms
Imperial College London 13
Not applicableLooking for participantsNCT07262138
What this trial is testing

Active Surveillance in Older Women With ER+ Breast Cancer

Who this might be right for
Early Stage Estrogen Receptor (ER) Positive Breast Cancer
University of Pittsburgh 50
Early research (Phase 1)Study completedNCT01273168
What this trial is testing

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

Who this might be right for
Hormone Receptor-Positive BreastGynecologicDesmoid+1 more
National Cancer Institute (NCI) 40
Large-scale testing (Phase 3)Not Yet RecruitingNCT07432178
What this trial is testing

CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）

Who this might be right for
Breast Cancer
Fudan University 2,288
Early research (Phase 1)Study completedNCT05364255
What this trial is testing

Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833

Who this might be right for
ER-positive, HER2-negative Breast Cancer
AstraZeneca 6
Testing effectiveness (Phase 2)Study completedNCT02954055
What this trial is testing

MEtronomic TrEatment Option in Advanced bReast cAncer

Who this might be right for
Breast Cancer
ETOP IBCSG Partners Foundation 140
Testing effectiveness (Phase 2)Active Not RecruitingNCT03359954
What this trial is testing

Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeInvasive Breast Carcinoma+1 more
M.D. Anderson Cancer Center 25
Large-scale testing (Phase 3)Active Not RecruitingNCT03725059
What this trial is testing

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Who this might be right for
Breast Cancer
Merck Sharp & Dohme LLC 1,240
Next Page